产品名称
18:0 DDAB, Avanti Research™ - A Croda Brand
SMILES string
CCCCCCCCCCCCCCCCCC[N+](CCCCCCCCCCCCCCCCCC)(C)C.[Br-]
InChI
1S/C38H80N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-38H2,1-4H3;1H/q+1;/p-1
InChI key
PSLWZOIUBRXAQW-UHFFFAOYSA-M
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 1 g (890810P-1g)
pkg of 1 × 200 mg (890810P-200mg)
pkg of 1 × 25 mg (890810P-25mg)
pkg of 1 × 500 mg (890810P-500mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
application(s)
vaccine development
lipid type
cationic lipids
transfection
shipped in
dry ice
storage temp.
−20°C
Application
18:0 DDAB适合制备脂质纳米颗粒。它还可用作佐剂，与单磷酸脂A（MPL）联合用于免疫小鼠。
Biochem/physiol Actions
18:0 DDAB是一种表面活性分子，可用作诱导全身免疫反应的佐剂。无毒。
General description
18:0 DDAB是阳离子脂质和季铵盐。与可电离的脂质不同，烃尾巴是饱和的。
Other Notes
仅供研发使用。& 不可用于药物、家庭或其他用途。
Packaging
20 mL透明玻璃螺旋盖样品瓶（890810P-1g）
20 mL透明玻璃螺旋盖样品瓶（890810P-500mg）
5 mL棕色玻璃螺旋盖样品瓶（890810P-200mg）
5 mL棕色玻璃螺旋盖样品瓶（890810P-25mg）
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens
Klinguer C, et al.
Vaccine, 19(30), 4236-4244 (2001)
Ana Cristina Norberto Oliveira et al.
ACS applied materials & interfaces, 6(9), 6977-6989 (2014-04-10)
This study describes a novel liposomal formulation for siRNA delivery, based on the mixture of the neutral lipid monoolein (MO) and cationic lipids of the dioctadecyldimethylammonium (DODA) family. The cationic lipids dioctadecyldimethylammonium bromide (DODAB) and chloride (DODAC) were compared in
Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
Lipid nanoparticles for delivery of messenger RNA to the back of the eye
Patel S, et al.
J. Controlled Release, 303, 91-100 (2019)
Hong Yu et al.
Infection and immunity, 80(4), 1510-1518 (2012-02-01)
Major impediments to a Chlamydia vaccine lie in discovering T cell antigens and polarizing adjuvants that stimulate protective immunity. We previously reported the discovery of three T cell antigens (PmpG, PmpF, and RplF) via immunoproteomics that elicited protective immunity in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持